Welcome to our dedicated page for Sigyn Therapeutics news (Ticker: SIGY), a resource for investors and traders seeking the latest updates and insights on Sigyn Therapeutics stock.
Sigyn Therapeutics, Inc. (SIGY) is a development-stage medical technology company whose news flow centers on its dialysis-like blood purification therapies and related corporate developments. Company announcements highlight progress on Sigyn Therapy, a novel blood purification technology aimed at pathogen-associated inflammatory disorders, as well as its oncology-focused platforms ImmunePrep, ChemoPrep, and ChemoPure.
News releases frequently cover clinical and regulatory milestones, such as plans for first-in-human feasibility studies of Sigyn Therapy in end-stage renal disease patients with endotoxemia and concurrent inflammation, drafting of an Investigational Device Exemption for submission to the U.S. Food and Drug Administration, and discussions of potential Breakthrough Device submissions. Investors can also find updates on annual and quarterly financial results, including the filing of Form 10-K and other SEC reports referenced in company communications.
Sigyn Therapeutics also issues news about capital markets and corporate actions, including its 1-for-40 reverse stock split and efforts to meet listing requirements for The Nasdaq Capital Market. Coverage includes participation in emerging growth and small-cap conferences, such as the Emerging Growth Conference and LD Micro Main Event, where management presents updates on the companys therapeutic pipeline and development plans.
In addition, third-party research coverage, such as reports from Goldman Small Cap Research, is sometimes summarized in press releases that describe Sigyn Therapeutics as a developer of next-generation blood purification therapies for life-threatening conditions without FDA-approved treatments. For investors and observers, the SIGY news feed offers a consolidated view of clinical planning, technology development, financing steps, and investor outreach activities related to the companys blood purification and oncology-support platforms.
Sigyn Therapeutics (OTC: SIGY) announced the successful completion of a pilot animal study validating its Sigyn Therapy™ for treating life-threatening inflammatory conditions. This marks the first use of the therapy in mammals, demonstrating safe administration without complications over six-hour treatment periods. Sigyn Therapy aims to capture a market exceeding $20 billion annually, specifically targeting conditions like sepsis. Following positive outcomes, the company plans additional studies and seeks FDA clearance to initiate human trials.
Sigyn Therapeutics, Inc. (OTCMarkets: SIGY) announced the completion of a study demonstrating the effectiveness of Sigyn Therapy™ in eliminating hepatic toxins like bile acid, bilirubin, and ammonia from human blood plasma. Results showed an 80.6% reduction of bile acid and 55% reduction of bilirubin in one hour. The therapy targets life-threatening inflammatory conditions, especially hepatic encephalopathy, which can have a 30-day mortality rate of 38% in severe cases. The company plans to submit an Investigational Device Exemption to the FDA by year-end 2021.
Sigyn Therapeutics, Inc. (OTCMarkets: SIGY) has completed an in vitro blood purification study, validating that Sigyn Therapy can eliminate toxins associated with Hepatic Encephalopathy, a severe neurological condition. The therapy showed a 55% reduction in bilirubin levels in just one hour and 69.5% over four hours. This innovative technology addresses the significant unmet need for life-threatening inflammatory conditions. Sigyn plans to submit data for an Investigational Device Exemption to the FDA by year-end 2021, potentially expanding its market presence valued at over $20 billion.
Sigyn Therapeutics announced a webinar scheduled for June 29, 2021, at 12 PM Eastern, featuring Chairman and CEO, Jim Joyce. The webinar will cover the evolution of blood purification technologies in response to pandemic threats, including COVID-19. Joyce will discuss the significance of blood purification therapies in treating life-threatening conditions, particularly those caused by Cytokine Storm Syndrome. The company aims to address a $20 billion market opportunity with its Sigyn Therapy, designed to mitigate inflammatory conditions like sepsis.
Sigyn Therapeutics (OTCMarkets: SIGY) announced that its Chairman and CEO, Jim Joyce, will present at the LD Micro Invitational Conference on June 8, 2021, at 5:30 PM ET. The conference is focused on advancements in treating life-threatening inflammatory conditions, including sepsis, via their innovative Sigyn Therapy™. This multifaceted blood purification technology targets the Cytokine Storm, a leading cause of in-hospital deaths, with a potential market exceeding $20 billion. Details of the event will be available via a webcast.
Sigyn Therapeutics (OTCMarkets: SIGY) announced a live corporate update webinar scheduled for May 21 at 11 am ET. CEO Jim Joyce will highlight milestones in advancing Sigyn Therapy™, a blood purification technology targeting life-threatening inflammatory conditions like sepsis. Topics include team expansion, improved financial status, and upcoming studies for an Investigational Device Exemption (IDE) submission to the FDA. The company aims to address severe conditions exacerbated by cytokine storm syndrome, which significantly impacts public health.
Sigyn Therapeutics (OTCMarkets: SIGY) announced promising results from in vitro studies of Sigyn Therapy™, a technology targeting life-threatening inflammatory conditions, particularly Cytokine Storm Syndrome. The therapy demonstrated a 68.8% reduction in SARS-CoV-2 pseudotyped lentivirus after a two-hour exposure. The company highlighted a market opportunity exceeding $20 billion in addressing Cytokine Storm-related indications. Sigyn has also submitted a provisional patent application to protect its findings and plans to submit an Investigational Device Exemption to the FDA in 2021.
Sigyn Therapeutics announces its videoconference event today at 4pm Eastern, featuring Chairman and CEO Jim Joyce. This interactive session provides an opportunity for investors to discuss Sigyn Therapy™, a novel blood purification technology aimed at treating life-threatening inflammatory conditions such as cytokine storm syndrome. The event also includes analyst Rob Goldman, who has begun coverage of Sigyn Therapeutics. Space is limited; registration is available through an online link.
Sigyn Therapeutics announced that its Chairman and CEO, Jim Joyce, will participate in a roundtable forum on March 17, 2021, at 12 PM ET, hosted by Rob Goldman of Goldman Small Cap Research. The discussion will focus on Sigyn Therapy™, a blood purification technology for treating life-threatening inflammatory conditions like sepsis, which stems from Cytokine Storm Syndrome. With high mortality rates linked to conditions like COVID-19, Sigyn aims to address significant unmet medical needs. For more details, visit www.SigynTherapeutics.com.
Sigyn Therapeutics, Inc. (OTCMarkets: SIGY) announced that its Chairman and CEO, Jim Joyce, will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation will be available from March 9 at 7:00 am EST on the company’s website and during the conference. Sigyn focuses on treating life-threatening inflammatory conditions linked to Cytokine Storm Syndrome, a major cause of sepsis-related deaths. Their Sigyn Therapy aims to mitigate these conditions through novel blood purification technology.